Go Pro
→ The $5 company SpaceX can’t survive without (From Traders Agency) (Ad)tc pixel Free ENSC Stock Alerts

Ensysce Biosciences (ENSC) Competitors

Ensysce Biosciences logo
$0.26 -0.02 (-6.72%)
As of 09:57 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

ENSC vs. AEON, AIMD, CMMB, TPST, and CTXR

Should you buy Ensysce Biosciences stock or one of its competitors? MarketBeat compares Ensysce Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ensysce Biosciences include AEON Biopharma (AEON), Ainos (AIMD), Chemomab Therapeutics (CMMB), Tempest Therapeutics (TPST), and Citius Pharmaceuticals (CTXR). These companies are all part of the "pharmaceutical products" industry.

How does Ensysce Biosciences compare to AEON Biopharma?

AEON Biopharma (NASDAQ:AEON) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

AEON Biopharma has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market. Comparatively, Ensysce Biosciences has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

Ensysce Biosciences has higher revenue and earnings than AEON Biopharma. Ensysce Biosciences is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AEON BiopharmaN/AN/A-$36.63M-$5.00N/A
Ensysce Biosciences$5.07M0.78-$10.18M-$3.35N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AEON Biopharma
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.00
Ensysce Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Ensysce Biosciences had 1 more articles in the media than AEON Biopharma. MarketBeat recorded 2 mentions for Ensysce Biosciences and 1 mentions for AEON Biopharma. Ensysce Biosciences' average media sentiment score of 1.44 beat AEON Biopharma's score of 0.00 indicating that Ensysce Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
AEON Biopharma Neutral
Ensysce Biosciences Positive

22.8% of AEON Biopharma shares are held by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are held by institutional investors. 9.4% of AEON Biopharma shares are held by company insiders. Comparatively, 2.8% of Ensysce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

AEON Biopharma has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -250.39%. AEON Biopharma's return on equity of 0.00% beat Ensysce Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
AEON BiopharmaN/A N/A -994.63%
Ensysce Biosciences -250.39%-766.45%-256.59%

Summary

AEON Biopharma beats Ensysce Biosciences on 8 of the 15 factors compared between the two stocks.

How does Ensysce Biosciences compare to Ainos?

Ensysce Biosciences (NASDAQ:ENSC) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

Ensysce Biosciences has higher revenue and earnings than Ainos. Ainos is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ensysce Biosciences$5.07M0.78-$10.18M-$3.35N/A
Ainos$120K131.71-$14.77M-$2.89N/A

In the previous week, Ensysce Biosciences had 1 more articles in the media than Ainos. MarketBeat recorded 2 mentions for Ensysce Biosciences and 1 mentions for Ainos. Ainos' average media sentiment score of 1.89 beat Ensysce Biosciences' score of 1.44 indicating that Ainos is being referred to more favorably in the news media.

Company Overall Sentiment
Ensysce Biosciences Positive
Ainos Very Positive

Ensysce Biosciences has a net margin of -250.39% compared to Ainos' net margin of -11,912.10%. Ainos' return on equity of -160.55% beat Ensysce Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Ensysce Biosciences-250.39% -766.45% -256.59%
Ainos -11,912.10%-160.55%-62.29%

5.6% of Ensysce Biosciences shares are owned by institutional investors. 2.8% of Ensysce Biosciences shares are owned by company insiders. Comparatively, 9.8% of Ainos shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Ensysce Biosciences has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, Ainos has a beta of 2.43, indicating that its share price is 143% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ensysce Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Ainos
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Ainos beats Ensysce Biosciences on 7 of the 13 factors compared between the two stocks.

How does Ensysce Biosciences compare to Chemomab Therapeutics?

Ensysce Biosciences (NASDAQ:ENSC) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Chemomab Therapeutics has lower revenue, but higher earnings than Ensysce Biosciences. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ensysce Biosciences$5.07M0.78-$10.18M-$3.35N/A
Chemomab TherapeuticsN/AN/A-$8.99M-$2.22N/A

5.6% of Ensysce Biosciences shares are owned by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are owned by institutional investors. 2.8% of Ensysce Biosciences shares are owned by company insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Chemomab Therapeutics has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -250.39%. Chemomab Therapeutics' return on equity of -89.03% beat Ensysce Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Ensysce Biosciences-250.39% -766.45% -256.59%
Chemomab Therapeutics N/A -89.03%-79.68%

Chemomab Therapeutics has a consensus target price of $25.00, suggesting a potential upside of 1,433.74%. Given Chemomab Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Chemomab Therapeutics is more favorable than Ensysce Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ensysce Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Chemomab Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Ensysce Biosciences has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, Chemomab Therapeutics has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market.

In the previous week, Chemomab Therapeutics had 4 more articles in the media than Ensysce Biosciences. MarketBeat recorded 6 mentions for Chemomab Therapeutics and 2 mentions for Ensysce Biosciences. Ensysce Biosciences' average media sentiment score of 1.44 beat Chemomab Therapeutics' score of 0.61 indicating that Ensysce Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Ensysce Biosciences Positive
Chemomab Therapeutics Positive

Summary

Chemomab Therapeutics beats Ensysce Biosciences on 11 of the 15 factors compared between the two stocks.

How does Ensysce Biosciences compare to Tempest Therapeutics?

Ensysce Biosciences (NASDAQ:ENSC) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

In the previous week, Ensysce Biosciences had 1 more articles in the media than Tempest Therapeutics. MarketBeat recorded 2 mentions for Ensysce Biosciences and 1 mentions for Tempest Therapeutics. Tempest Therapeutics' average media sentiment score of 1.89 beat Ensysce Biosciences' score of 1.44 indicating that Tempest Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Ensysce Biosciences Positive
Tempest Therapeutics Very Positive

Ensysce Biosciences has higher revenue and earnings than Tempest Therapeutics. Tempest Therapeutics is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ensysce Biosciences$5.07M0.78-$10.18M-$3.35N/A
Tempest TherapeuticsN/AN/A-$26.26M-$6.01N/A

Tempest Therapeutics has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -250.39%. Tempest Therapeutics' return on equity of -355.61% beat Ensysce Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Ensysce Biosciences-250.39% -766.45% -256.59%
Tempest Therapeutics N/A -355.61%-121.21%

5.6% of Ensysce Biosciences shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 2.8% of Ensysce Biosciences shares are owned by company insiders. Comparatively, 36.3% of Tempest Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Ensysce Biosciences has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.73, suggesting that its share price is 273% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ensysce Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Tempest Therapeutics
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Summary

Tempest Therapeutics beats Ensysce Biosciences on 7 of the 13 factors compared between the two stocks.

How does Ensysce Biosciences compare to Citius Pharmaceuticals?

Citius Pharmaceuticals (NASDAQ:CTXR) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Citius Pharmaceuticals currently has a consensus target price of $5.00, suggesting a potential upside of 812.41%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Citius Pharmaceuticals is more favorable than Ensysce Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Citius Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Ensysce Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Ensysce Biosciences had 1 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 2 mentions for Ensysce Biosciences and 1 mentions for Citius Pharmaceuticals. Citius Pharmaceuticals' average media sentiment score of 1.87 beat Ensysce Biosciences' score of 1.44 indicating that Citius Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Citius Pharmaceuticals Very Positive
Ensysce Biosciences Positive

Ensysce Biosciences has higher revenue and earnings than Citius Pharmaceuticals. Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Citius PharmaceuticalsN/AN/A-$37.43M-$2.13N/A
Ensysce Biosciences$5.07M0.78-$10.18M-$3.35N/A

Citius Pharmaceuticals has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -250.39%. Citius Pharmaceuticals' return on equity of -61.09% beat Ensysce Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Citius PharmaceuticalsN/A -61.09% -35.36%
Ensysce Biosciences -250.39%-766.45%-256.59%

16.9% of Citius Pharmaceuticals shares are held by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are held by institutional investors. 5.0% of Citius Pharmaceuticals shares are held by company insiders. Comparatively, 2.8% of Ensysce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Citius Pharmaceuticals has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, Ensysce Biosciences has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

Summary

Citius Pharmaceuticals beats Ensysce Biosciences on 11 of the 15 factors compared between the two stocks.

Get Ensysce Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENSC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENSC vs. The Competition

Export
MetricEnsysce BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.90M$3.71B$7.05B$12.61B
Dividend YieldN/A2.20%2.68%8.00%
P/E Ratio-0.0820.8527.1024.26
Price / Sales0.78314.01588.85117.88
Price / CashN/A61.9829.2249.36
Price / Book0.418.4910.856.29
Net Income-$10.18M$23.83M$3.58B$330.66M
7 Day Performance-6.88%-3.56%-2.12%-1.35%
1 Month Performance2.31%6.31%3.27%-0.64%
1 Year Performance-88.32%48.30%26.33%19.08%

Ensysce Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ENSC
Ensysce Biosciences
1.5302 of 5 stars		$0.26
-6.7%		N/A-87.2%$3.90M$5.07MN/A10
AEON
AEON Biopharma
0.7575 of 5 stars		$0.70
-4.1%		N/A-61.7%$17.72MN/A3.895
AIMD
Ainos
1.0939 of 5 stars		$1.88
-7.8%		N/A-36.2%$17.39M$120KN/A40
CMMB
Chemomab Therapeutics
2.0221 of 5 stars		$2.77
+15.4%		$25.00
+802.5%		-64.3%$17.28MN/AN/A20
TPST
Tempest Therapeutics
1.3473 of 5 stars		$0.99
-7.4%		N/A-85.8%$17.10MN/AN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ENSC) was last updated on 7/14/2026 by MarketBeat.com Staff.
From Our Partners
The $5 company SpaceX can’t survive without
The investors who got rich on AI didn't all buy Nvidia. Some bought ASML, the company that makes the machines ...
Traders Agency | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
They told you not to miss this one
The largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...
Thor Metals | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
American’s Biggest Threat Is Here
This feels like one of those ''where were you when Kennedy was shot'' moments. It felt like a moment in time, ...
Goldco Direct, LLC | Sponsoredtc pixel
They proved it worked in '76. Then buried it.
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel